Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Dyslipidemia and lipid peroxidation of Saudi type 2 diabetics with proliferative retinopathy.

Aldebasi YH, Mohieldein AH, Almansour YS, Almutairi BL.

Saudi Med J. 2013 Jun;34(6):616-22.

PMID:
23756927
2.

Low serum apolipoprotein A1/B ratio is associated with proliferative diabetic retinopathy in type 2 diabetes.

Hu A, Luo Y, Li T, Guo X, Ding X, Zhu X, Wang X, Tang S.

Graefes Arch Clin Exp Ophthalmol. 2012 Jul;250(7):957-62. doi: 10.1007/s00417-011-1855-x. Epub 2012 Feb 12.

PMID:
22327732
3.

Levels of inflammatory markers and their correlation with dyslipidemia in diabetics.

Waheed P, Naveed AK, Farooq F.

J Coll Physicians Surg Pak. 2009 Apr;19(4):207-10. doi: 04.2009/JCPSP.207210.

PMID:
19356332
4.

Lipid peroxidation and antioxidant enzyme levels in type 2 diabetics with microvascular complications.

Kesavulu MM, Giri R, Kameswara Rao B, Apparao C.

Diabetes Metab. 2000 Nov;26(5):387-92.

PMID:
11119018
5.

Association between subclinical hypothyroidism and proliferative diabetic retinopathy in type 2 diabetic patients: a case-control study.

Yang GR, Yang JK, Zhang L, An YH, Lu JK.

Tohoku J Exp Med. 2010 Dec;222(4):303-10.

PMID:
21139382
6.

Effects of policosanol and lovastatin on lipid profile and lipid peroxidation in patients with dyslipidemia associated with type 2 diabetes mellitus.

Castaño G, Menéndez R, Más R, Amor A, Fernández JL, González RL, Lezcay M, Alvarez E.

Int J Clin Pharmacol Res. 2002;22(3-4):89-99.

PMID:
12837046
7.
8.

Insulin resistance and proliferative retinopathy: a cross-sectional, case-control study in 115 patients with type 2 diabetes.

Parvanova A, Iliev I, Filipponi M, Dimitrov BD, Vedovato M, Tiengo A, Trevisan R, Remuzzi G, Ruggenenti P.

J Clin Endocrinol Metab. 2004 Sep;89(9):4371-6.

PMID:
15356034
9.

High serum lipoprotein(a) levels in Korean type 2 diabetic patients with proliferative diabetic retinopathy.

Kim CH, Park HJ, Park JY, Hong SK, Yoon YH, Lee KU.

Diabetes Care. 1998 Dec;21(12):2149-51.

PMID:
9839109
10.

The impact of outpatient diabetes management on serum lipids in urban African-Americans with type 2 diabetes.

Erdman DM, Cook CB, Greenlund KJ, Giles WH, El-Kebbi I, Ryan GJ, Gallina DL, Ziemer DC, Dunbar VG, Phillips LS.

Diabetes Care. 2002 Jan;25(1):9-15.

PMID:
11772894
11.

Association of systemic risk factors with the severity of retinal hard exudates in a north Indian population with type 2 diabetes.

Sachdev N, Sahni A.

J Postgrad Med. 2010 Jan-Mar;56(1):3-6. doi: 10.4103/0022-3859.62419.

PMID:
20393241
12.

The effect of glycemic control in type 2 diabetic patients with diabetes-related dyslipidemia.

Abdel-Gayoum AG.

Saudi Med J. 2004 Feb;25(2):207-11.

PMID:
14968220
13.
14.
15.

The pattern of dyslipidemia among urban African-Americans with type 2 diabetes.

Cook CB, Erdman DM, Ryan GJ, Greenlund KJ, Giles WH, Gallina DL, El-Kebbi IM, Ziemer DC, Ernst KL, Dunbar VG, Phillips LS.

Diabetes Care. 2000 Mar;23(3):319-24.

PMID:
10868858
17.

Relationship of vascular endothelial growth factor (VEGF) +405 G/C polymorphism and proliferative retinopathy in patients with type 2 diabetes.

Feghhi M, Nikzamir A, Esteghamati A, Mahmoudi T, Yekaninejad MS.

Transl Res. 2011 Aug;158(2):85-91. doi: 10.1016/j.trsl.2011.03.002. Epub 2011 Apr 1.

PMID:
21757152
18.
19.

Plasma malondialdehyde (MDA) and anti-oxidant status in diabetic retinopathy.

Kumawat M, Kharb S, Singh V, Singh N, Singh SK, Nada M.

J Indian Med Assoc. 2014 Jan;112(1):29-32.

PMID:
25935946
20.

Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus.

Keating GM.

Am J Cardiovasc Drugs. 2011 Aug 1;11(4):227-47. doi: 10.2165/11207690-000000000-00000. Review.

PMID:
21675801
Items per page

Supplemental Content

Write to the Help Desk